Effects of F‐180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension
Cristina Bernadich, Juan‐Carlos Bandi, Per Melin, Jaime Bosch – 30 December 2003 – The present study is aimed at characterizing the portal, splanchnic, and systemic circulatory effects of F‐180, a new long‐acting analog of vasopressin (VP) with selective effect on the vascular (V1 ) receptor, both in normal rats and in portal‐hypertensive animals. In preliminary vasopressor tests, F‐180 was 18 times more potent than terlipressin (TP) (164 ± 10 IU × mmol−1 vs. 9.2 ± 1.2 IU × mmol−1) and four times less potent than arginine VP (614 ± 25 IU × mmol−1).